Eupatilin Inhibits Renal Cancer Growth by Downregulating MicroRNA-21 through the Activation of YAP1
Figure 6
Potential role of the YAP1-signaling pathway in miR-21 reduction by Eupatilin in vitro. (a) The expression of YAP1 and p-AKT was detected by immunohistochemistry in 20 pairs of renal cell carcinoma and healthy tissues. Representative images are shown. (b) 786-O cells were infected with negative control lentivirus (miR-NC), miR-21 mimics (miR-21), or miR-21 plus YAP1 (miR-21+YAP1) and treated with Eupatilin for 24 h. The expression of YAP1, p-AKT, and AKT in 786-O cells was assessed by western blotting. (c) Quantification of the results in (b). Data represent the mean ± SEM (n = 3) of three independent experiments. (P < 0.01 versus miR-NC; ## P < 0.01 versus miR-21). (d) 786-O cells were infected with negative control lentivirus (miR-NC), miR-21 mimics (miR-21), or miR-21 plus YAP1 (miR-21+YAP1) and treated with Eupatilin for 24 h. The apoptosis of 786-O cells was detected by flow cytometry. (e) Quantification of the results in (d). Data represent the mean ± SEM (n = 3) of three independent experiments. (P < 0.01 versus miR-NC; ## P < 0.01 versus miR-21). (f) 786-O cells were infected with negative control lentivirus (miR-NC), miR-21 mimics (miR-21), or miR-21 plus YAP1 (miR-21+YAP1) and treated with Eupatilin for 24 h. The migration ability of 786-O cells was detected using the Transwell assay. (g) Quantification of the results in (f). Data represent the mean ± SEM (n = 3) of three independent experiments. (P < 0.01 versus miR-NC; ## P < 0.01 versus miR-21).